Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
NCT05868876Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2023
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK127 in cancer, sponsored by Akeso, Inc. Primary endpoints: Adverse Events, Serious Adverse Events and 5 more. Started Jul 2023; status: completed.
02
Drugs
AK127
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05868876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868876.